Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has worked conscientiously but unsuccessfully to create a single therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this therapy, CytoDyn has cast its net far and wide both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be used is actually an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as a combination therapy in the treatment of multi-drug-resistant HIV have been closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past several shares. My 1st CytoDyn post, “CytoDyn: What To Do When It is Too Good to be able to Be True?”, set away all of the following prediction:

Instead I expect it to become a serial disappointer. CEO Pourhassan offered such an extremely promotional picture in the Uptick Newswire interview that I came away with an inadequate impression of the business.

Irony of irony, my poor viewpoint of the business enterprise has grown steadily, although the disappointment hasn’t been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein lies the story; let me explain.

CytoDyn acquired its much-storied therapy (which I shall mean as leronlimab) back during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) focusing on the CCR5 receptor for your treatment and reduction of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s payment of $3.5 huge number of transfers ownership of this know-how as well as connected intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a level III clinical trial ($1.5 zillion) along with the very first brand new drug application approval ($5 million), and even royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition into a springboard for CytoDyn to acquire a market cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and many indications, it’s this individual therapies in addition to a “broad pipeline of indications” since it places it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially beneficial therapy in dozens of indications.

Its opening banner on the website of its (below) shows an active organization with diverse interests albeit focused on leronlimab, several illness types, multiple delivering presentations in addition to multiple publications.

Can all this be smoke cigarettes and mirrors? That is a question I have been asking myself from the really beginning of the interest of mine in this particular company. Judging with the multiples of thousands of several commentary on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I am far from alone in this question.

CytoDyn is a classic battleground, or maybe some could say cult inventory. Its adherents are fiercely protective of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *